GammaTile Therapy is a cutting-edge novel approach to treating brain tumors. Dr. Ranjith Babu joins to address the process and benefits of GammaTile Therapy.
Arizona Center for Cancer Care (AZCCC) today announced its 100th patient treated with GammaTile® Therapy, a Surgically Targeted Radiation Therapy (STaRT) for brain tumors.
GT Medical Technologies’ implant delivers radiation therapy directly to the bed of an excised brain tumor—a potential game-changer for people with highly proliferative, hard-to-treat tumors such as glioblastomas. Its GammaTile Therapy is now in use at 75 US hospitals and the firm has raised $26 million over the past three years—not bad for a company that launched its flagship product at the height of the pandemic.
GT Medical announced the first participant enrolled in the GammaTile Enhanced Stupp ALTernative (GESTALT) trial. While this trial is still in its infancy, if the results are favorable, it may influence protocols for treating glioblastomas (GBMs) and bridge the gap between surgery and chemoradiation.
Enrolling Newly Diagnosed Patients with Glioblastoma in the GESTALT Clinical Trial
UC San Diego Health is the first hospital system in San Diego to offer a new, highly targeted and precisely placed radiation therapy that delays tumor regrowth while protecting healthy tissue in patients with brain cancer.
Doctors at UofL Health are the first in the state to use a new brain cancer radiation treatment called the gamma tile.
GammaTile, a tiny device implanted into the brain in a space a tumor used to fill which delivers targeted radiation therapy.
Westchester Medical Center recently became the first neurosurgical oncology program in the Hudson Valley* to offer a targeted therapy for brain tumors that can help delay tumor progression, spare healthy tissue and reduce the number of post-surgical radiation treatments – and the side effects that come along with them.
GT Medical Technologies’ GammaTile is a surgically targeted radiation therapy (STaRT) for brain tumors. GT Medical Technologies designed the GammaTile to provide immediate, dose-intense treatment at the completion of resection. The company says the therapy system can extend local recurrence-free survival with minimal complications to reduce patient burden and assure compliance.